Copyright Reports & Markets. All rights reserved.

Global Acute Intermittent Porphyria Therapeutics Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope of Acute Intermittent Porphyria Therapeutics
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Acute Intermittent Porphyria Therapeutics by Type
    • 1.3.1 Overview: Global Acute Intermittent Porphyria Therapeutics Market Size by Type: 2019 Versus 2023 Versus 2030
    • 1.3.2 Global Acute Intermittent Porphyria Therapeutics Consumption Value Market Share by Type in 2023
    • 1.3.3 350mg
    • 1.3.4 313mg
  • 1.4 Global Acute Intermittent Porphyria Therapeutics Market by Application
    • 1.4.1 Overview: Global Acute Intermittent Porphyria Therapeutics Market Size by Application: 2019 Versus 2023 Versus 2030
    • 1.4.2 Hospital
    • 1.4.3 Pharmacy
  • 1.5 Global Acute Intermittent Porphyria Therapeutics Market Size & Forecast
  • 1.6 Global Acute Intermittent Porphyria Therapeutics Market Size and Forecast by Region
    • 1.6.1 Global Acute Intermittent Porphyria Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
    • 1.6.2 Global Acute Intermittent Porphyria Therapeutics Market Size by Region, (2019-2030)
    • 1.6.3 North America Acute Intermittent Porphyria Therapeutics Market Size and Prospect (2019-2030)
    • 1.6.4 Europe Acute Intermittent Porphyria Therapeutics Market Size and Prospect (2019-2030)
    • 1.6.5 Asia-Pacific Acute Intermittent Porphyria Therapeutics Market Size and Prospect (2019-2030)
    • 1.6.6 South America Acute Intermittent Porphyria Therapeutics Market Size and Prospect (2019-2030)
    • 1.6.7 Middle East and Africa Acute Intermittent Porphyria Therapeutics Market Size and Prospect (2019-2030)

2 Company Profiles

  • 2.1 Recordati Rare Diseases
    • 2.1.1 Recordati Rare Diseases Details
    • 2.1.2 Recordati Rare Diseases Major Business
    • 2.1.3 Recordati Rare Diseases Acute Intermittent Porphyria Therapeutics Product and Solutions
    • 2.1.4 Recordati Rare Diseases Acute Intermittent Porphyria Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
    • 2.1.5 Recordati Rare Diseases Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Acute Intermittent Porphyria Therapeutics Revenue and Share by Players (2019-2024)
  • 3.2 Market Share Analysis (2023)
    • 3.2.1 Market Share of Acute Intermittent Porphyria Therapeutics by Company Revenue
    • 3.2.2 Top 3 Acute Intermittent Porphyria Therapeutics Players Market Share in 2023
    • 3.2.3 Top 6 Acute Intermittent Porphyria Therapeutics Players Market Share in 2023
  • 3.3 Acute Intermittent Porphyria Therapeutics Market: Overall Company Footprint Analysis
    • 3.3.1 Acute Intermittent Porphyria Therapeutics Market: Region Footprint
    • 3.3.2 Acute Intermittent Porphyria Therapeutics Market: Company Product Type Footprint
    • 3.3.3 Acute Intermittent Porphyria Therapeutics Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Acute Intermittent Porphyria Therapeutics Consumption Value and Market Share by Type (2019-2024)
  • 4.2 Global Acute Intermittent Porphyria Therapeutics Market Forecast by Type (2025-2030)

5 Market Size Segment by Application

  • 5.1 Global Acute Intermittent Porphyria Therapeutics Consumption Value Market Share by Application (2019-2024)
  • 5.2 Global Acute Intermittent Porphyria Therapeutics Market Forecast by Application (2025-2030)

6 North America

  • 6.1 North America Acute Intermittent Porphyria Therapeutics Consumption Value by Type (2019-2030)
  • 6.2 North America Acute Intermittent Porphyria Therapeutics Consumption Value by Application (2019-2030)
  • 6.3 North America Acute Intermittent Porphyria Therapeutics Market Size by Country
    • 6.3.1 North America Acute Intermittent Porphyria Therapeutics Consumption Value by Country (2019-2030)
    • 6.3.2 United States Acute Intermittent Porphyria Therapeutics Market Size and Forecast (2019-2030)
    • 6.3.3 Canada Acute Intermittent Porphyria Therapeutics Market Size and Forecast (2019-2030)
    • 6.3.4 Mexico Acute Intermittent Porphyria Therapeutics Market Size and Forecast (2019-2030)

7 Europe

  • 7.1 Europe Acute Intermittent Porphyria Therapeutics Consumption Value by Type (2019-2030)
  • 7.2 Europe Acute Intermittent Porphyria Therapeutics Consumption Value by Application (2019-2030)
  • 7.3 Europe Acute Intermittent Porphyria Therapeutics Market Size by Country
    • 7.3.1 Europe Acute Intermittent Porphyria Therapeutics Consumption Value by Country (2019-2030)
    • 7.3.2 Germany Acute Intermittent Porphyria Therapeutics Market Size and Forecast (2019-2030)
    • 7.3.3 France Acute Intermittent Porphyria Therapeutics Market Size and Forecast (2019-2030)
    • 7.3.4 United Kingdom Acute Intermittent Porphyria Therapeutics Market Size and Forecast (2019-2030)
    • 7.3.5 Russia Acute Intermittent Porphyria Therapeutics Market Size and Forecast (2019-2030)
    • 7.3.6 Italy Acute Intermittent Porphyria Therapeutics Market Size and Forecast (2019-2030)

8 Asia-Pacific

  • 8.1 Asia-Pacific Acute Intermittent Porphyria Therapeutics Consumption Value by Type (2019-2030)
  • 8.2 Asia-Pacific Acute Intermittent Porphyria Therapeutics Consumption Value by Application (2019-2030)
  • 8.3 Asia-Pacific Acute Intermittent Porphyria Therapeutics Market Size by Region
    • 8.3.1 Asia-Pacific Acute Intermittent Porphyria Therapeutics Consumption Value by Region (2019-2030)
    • 8.3.2 China Acute Intermittent Porphyria Therapeutics Market Size and Forecast (2019-2030)
    • 8.3.3 Japan Acute Intermittent Porphyria Therapeutics Market Size and Forecast (2019-2030)
    • 8.3.4 South Korea Acute Intermittent Porphyria Therapeutics Market Size and Forecast (2019-2030)
    • 8.3.5 India Acute Intermittent Porphyria Therapeutics Market Size and Forecast (2019-2030)
    • 8.3.6 Southeast Asia Acute Intermittent Porphyria Therapeutics Market Size and Forecast (2019-2030)
    • 8.3.7 Australia Acute Intermittent Porphyria Therapeutics Market Size and Forecast (2019-2030)

9 South America

  • 9.1 South America Acute Intermittent Porphyria Therapeutics Consumption Value by Type (2019-2030)
  • 9.2 South America Acute Intermittent Porphyria Therapeutics Consumption Value by Application (2019-2030)
  • 9.3 South America Acute Intermittent Porphyria Therapeutics Market Size by Country
    • 9.3.1 South America Acute Intermittent Porphyria Therapeutics Consumption Value by Country (2019-2030)
    • 9.3.2 Brazil Acute Intermittent Porphyria Therapeutics Market Size and Forecast (2019-2030)
    • 9.3.3 Argentina Acute Intermittent Porphyria Therapeutics Market Size and Forecast (2019-2030)

10 Middle East & Africa

  • 10.1 Middle East & Africa Acute Intermittent Porphyria Therapeutics Consumption Value by Type (2019-2030)
  • 10.2 Middle East & Africa Acute Intermittent Porphyria Therapeutics Consumption Value by Application (2019-2030)
  • 10.3 Middle East & Africa Acute Intermittent Porphyria Therapeutics Market Size by Country
    • 10.3.1 Middle East & Africa Acute Intermittent Porphyria Therapeutics Consumption Value by Country (2019-2030)
    • 10.3.2 Turkey Acute Intermittent Porphyria Therapeutics Market Size and Forecast (2019-2030)
    • 10.3.3 Saudi Arabia Acute Intermittent Porphyria Therapeutics Market Size and Forecast (2019-2030)
    • 10.3.4 UAE Acute Intermittent Porphyria Therapeutics Market Size and Forecast (2019-2030)

11 Market Dynamics

  • 11.1 Acute Intermittent Porphyria Therapeutics Market Drivers
  • 11.2 Acute Intermittent Porphyria Therapeutics Market Restraints
  • 11.3 Acute Intermittent Porphyria Therapeutics Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 Acute Intermittent Porphyria Therapeutics Industry Chain
  • 12.2 Acute Intermittent Porphyria Therapeutics Upstream Analysis
  • 12.3 Acute Intermittent Porphyria Therapeutics Midstream Analysis
  • 12.4 Acute Intermittent Porphyria Therapeutics Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Acute Intermittent Porphyria Therapeutics market size was valued at USD 50 million in 2023 and is forecast to a readjusted size of USD 56 million by 2030 with a CAGR of 1.7% during review period.
    Acute intermittent porphyria (AIP), also called Swedish porphyria, pyrroloporphyria, intermittent acute porphyria) is a rare autosomal dominant metabolic disorder affecting the production of heme resulting from a deficiency of the porphobilinogen deaminase. It is the most common of the acute porphyrias.
    Panhematin (hemin) is a medication used to treat acute porphyria, a rare genetic disorder that affects heme production. Its effectiveness in managing acute porphyria attacks and reducing symptoms has driven market growth. The rarity of the condition and limited treatment options contribute to its niche status. However, challenges include the need for careful monitoring and potential side effects. The market competition is relatively small, as Panhematin remains a specialized therapy.
    The Global Info Research report includes an overview of the development of the Acute Intermittent Porphyria Therapeutics industry chain, the market status of Hospital (350mg, 313mg), Pharmacy (350mg, 313mg), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Acute Intermittent Porphyria Therapeutics.
    Regionally, the report analyzes the Acute Intermittent Porphyria Therapeutics markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Acute Intermittent Porphyria Therapeutics market, with robust domestic demand, supportive policies, and a strong manufacturing base.
    Key Features:
    The report presents comprehensive understanding of the Acute Intermittent Porphyria Therapeutics market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Acute Intermittent Porphyria Therapeutics industry.
    The report involves analyzing the market at a macro level:
    Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., 350mg, 313mg).
    Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Acute Intermittent Porphyria Therapeutics market.
    Regional Analysis: The report involves examining the Acute Intermittent Porphyria Therapeutics market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
    Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Acute Intermittent Porphyria Therapeutics market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
    The report also involves a more granular approach to Acute Intermittent Porphyria Therapeutics:
    Company Analysis: Report covers individual Acute Intermittent Porphyria Therapeutics players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
    Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Acute Intermittent Porphyria Therapeutics This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hospital, Pharmacy).
    Technology Analysis: Report covers specific technologies relevant to Acute Intermittent Porphyria Therapeutics. It assesses the current state, advancements, and potential future developments in Acute Intermittent Porphyria Therapeutics areas.
    Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Acute Intermittent Porphyria Therapeutics market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
    Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
    Market Segmentation
    Acute Intermittent Porphyria Therapeutics market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
    Market segment by Type
    350mg
    313mg
    Market segment by Application
    Hospital
    Pharmacy
    Market segment by players, this report covers
    Recordati Rare Diseases
    Market segment by regions, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
    South America (Brazil, Argentina and Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 13 chapters:
    Chapter 1, to describe Acute Intermittent Porphyria Therapeutics product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top players of Acute Intermittent Porphyria Therapeutics, with revenue, gross margin and global market share of Acute Intermittent Porphyria Therapeutics from 2019 to 2024.
    Chapter 3, the Acute Intermittent Porphyria Therapeutics competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
    Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
    Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Acute Intermittent Porphyria Therapeutics market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
    Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
    Chapter 12, the key raw materials and key suppliers, and industry chain of Acute Intermittent Porphyria Therapeutics.
    Chapter 13, to describe Acute Intermittent Porphyria Therapeutics research findings and conclusion.

    Buy now